The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 01, 2022

Filed:

May. 31, 2017
Applicant:

Polyphor Ag, Allschwil, CH;

Inventors:

Christian Ludin, Oberwil, CH;

Manfred Keller, Munich, DE;

Piet Bruijnzeel, Utrecht, NL;

Johann Zimmermann, Mullheim, DE;

Philip Barth, Basel, CH;

Eric Chevalier, Steinbrunn-le-bas, FR;

Assignee:

POLYPHOR AG, Allschwil, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/12 (2006.01); A61P 11/08 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/12 (2013.01); A61K 9/0073 (2013.01); A61P 11/08 (2018.01);
Abstract

The present invention relates to pharmaceutical aerosols comprising a β-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-Pro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity. Thus, the invention further relates to a pharmaceutical composition or a pharmaceutical aerosol comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-Pro-Pro-), or any pharmaceutically acceptable salt thereof, for use in a method for the prevention, management or treatment of diseases or conditions of the lungs being mediated by or resulting from human neutrophil elastase activity in a subject.


Find Patent Forward Citations

Loading…